protein phosphatase, Mg2+/Mn2+ dependent 1AGenealiases: PP2C-ALPHA · PP2CA · PP2Calpha
Q-omics provides the consensus-scored PPM1A profile across patient tissues and cancer cell-line models. PPM1A expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PPM1A is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, PPM1A protein abundance shows 21,293 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where PPM1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPM1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPM1A survival associations across molecular data types. PPM1A RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPM1A RNA expression–survival associations across cancer types. High PPM1A expression shows unfavorable associations in UVM and THCA, but favorable associations in KIRC, UCS, BRCA and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PPM1A RNA expression.
This table summarizes PPM1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PPM1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPM1A shows lower tumor expression in COAD, KIRC, THCA and READ and higher tumor expression in HNSC and LIHC. The COAD box plot shows higher PPM1A RNA expression in normal versus tumor tissue (log2 FC = −0.868, t-test p < 0.001).
This table shows molecular features associated with PPM1A in patient tissues and cancer cell lines. In patient samples, PPM1A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PPM1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
